BIMIRALISIB

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H20F3N7O2
Molecular Weight	411.3816
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC=C(C2=NC(=NC(=N2)N3CCOCC3)N4CCOCC4)C(=C1)C(F)(F)F

InChI

InChIKey=ADGGYDAFIHSYFI-UHFFFAOYSA-N

InChI=1S/C17H20F3N7O2/c18-17(19,20)12-9-13(21)22-10-11(12)14-23-15(26-1-5-28-6-2-26)25-16(24-14)27-3-7-29-8-4-27/h9-10H,1-8H2,(H2,21,22)

HIDE SMILES / InChI

Molecular Formula	C17H20F3N7O2
Molecular Weight	411.3816
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pan-pi3k-mtor-inhibitor-pqr309 | https://adisinsight.springer.com/drugs/800038844 | https://www.ncbi.nlm.nih.gov/pubmed/29660598

PQR-309 is an orally bioavailable pan inhibitor of phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. PI3K/mTOR kinase inhibitor PQR-309 inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K/mTOR. By inhibiting mTOR to a lesser extent than PI3K, PQR-309 does not interfere with the mTOR-mediated negative feedback loop on PI3K signaling. Blocking the negative feedback loop would potentially increase PI3K signaling and decrease therapeutic efficacy. PQR-309 is in phase II clinical trial for the treatment of glioblastoma, head and neck cancer, lymphoma and breast cancer. Common adverse events included fatigue, hyperglycemia, nausea, diarrhea, constipation, rash, anorexia and vomiting.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serine/threonine-protein kinase mTOR 35 Target ID: CHEMBL2842 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29066507	Inhibitor 8504
Phosphoinositide-3-kinase 3 Target ID: Phosphoinositide-3-kinase Sources: https://www.ncbi.nlm.nih.gov/pubmed/29066507	Inhibitor 8504

C_max

Value	Dose	Co-administered	Analyte	Population
766 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/38539472/	80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BIMIRALISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
4090 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/38539472/	80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BIMIRALISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
39.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/38539472/	80 mg 1 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BIMIRALISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

PubMed

Title	Date	PubMed
Big Hopes with Small Molecules - PIQUR Therapeutics AG is aiming to Turn Cancer into a Manageable Disease.	2014 Dec	26508614
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.	2017 Sep 14	28829592
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.	2018 Jan 1	29066507
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).	2018 Jun	29660598

Sample Use Guides

In Vivo Use Guide

80 mg once-daily

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:26:58 GMT 2025` Edited by `admin` on `Mon Mar 31 22:26:58 GMT 2025`
Record UNII	6Z3QHB00LB
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

bimiralisib [INN]

Preferred Name

English

BIMIRALISIB

Official Name

English

Bimiralisib [WHO-DD]

Common Name

English

NC-B5

Code

English

2-PYRIDINAMINE, 5-(4,6-DI-4-MORPHOLINYL-1,3,5-TRIAZIN-2-YL)-4-(TRIFLUOROMETHYL)-

Systematic Name

English

NCB5

Code

English

PQR-309

Code

English

5-(4,6-Dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine

Systematic Name

English

PQR309

Code

English

PI3K-IN-2

Code

English

BIMIRALISIB [USAN]

Common Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/17/1830